Emergent New Anti PD-1/PD-L1 Small Molecules for Cancer Treatment
Armen Andreasyan & Luis Mendoza · International Research Journal of Oncology · 2022
Currently all approved PD-1/PD-L1 inhibitors are monoclonal antibodies. Along with that, compounds from other chemical classes are being investigated as well. Among those are small molecules which demonstrate commensurable therapeutic effect in preclinical and early clinical deve...
Open access
Research Article